Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + zoledronic acid
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy of sorafenib and zoledronic acid used for the treatment of hepatocellular carcinoma. Sorafenib is a multiple kinase inhibitor that inhibits the Raf/MEK/ERK signaling pathway to decrease tumor growth and angiogenesis, while zoledronic acid is a bisphosphonate that depletes macrophages. The combination has shown synergistic effects in inhibiting tumor progression, angiogenesis, and metastasis compared to sorafenib alone.
02
Targets
BRAF V600EFLT3 (Fms related receptor tyrosine kinase 3)FDPS (Farnesyl pyrophosphate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sorafenib + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + zoledronic acid.